*December 2020*

EGFRALK, and ROS1 abnormalities are no longer the only oncogenic drivers worthy of discussion in non–small cell lung cancer (NSCLC), explained Stephen Liu, MD, who added that the field has seen an abundance of highly selective RET, MET, HER2, and KRAS inhibitors that have the potential to deliver durable responses.

“One of the most exciting areas of lung cancer is our ability to increasingly subdivide the disease into different molecular types. Although we are comfortable with treating patients with EGFR– and ALK-, and ROS1-positive lung cancers differently, we’re learning that, in NSCLC, there many other subtypes that represent different biologies, and we now have the tools to really treat those differently,” said Liu.

In an interview with OncLive® during the 2020 Institutional Perspectives on Cancer webinar on lung cancer, Liu, associate professor of medicine, Division of Hematology and Oncology, Georgetown University Medical Center, discussed some pivotal data that support the expanding reach of targeted therapy in NSCLC. Read more.